BiologicalDrug
Telitacicept clinical trials
Also written RC18.
- studies test it
- 53
- open now
- 27
- in phase 3
- 18
- first study started
- 2015
Keep track of what changes. Save the telitacicept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- RC18
- 13
Combined with it in one product
Studies by the year they started
53 studies that test it; most in 2023 (13)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 7 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 20
- Phase 3
- 18
- Phase 4
- 8
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 29
RemeGen Co., Ltd. (19) · Vor Biopharma (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Chinese SLE Treatment And Research Group (3) · Renmin Hospital of Wuhan University (2) · Ruijin Hospital (2) · The Children's Hospital of Zhejiang University School of Medicine (2) · First Affiliated Hospital of Wenzhou Medical University (2)
Often tested with
Tested in the same studies.
IBI3034 (1) · Efgartigimod alfa (1) · Cyclophosphamide (1) · Belimumab (1) · Mycophenolic Acid (1) · Interleukin-2 (1)
Studies
Open first, then newest update. How each study uses telitacicept is read from its arms, and is right about nine times in ten.
Testing it · 53
- IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyNot yet recruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT07886476Written as Telitacicept
- Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseRecruitingPhase 3Vor BiopharmaNCT07404865Written as Telitacicept
- Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid ArthritisRecruitingPhase 2Peking University People's HospitalNCT07796516Written as Telitacicept 160mg
- Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung DiseaseNot yet recruitingPhase 3RemeGen Co., Ltd.NCT07495033Written as Telitacicept
- A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RecruitingPhase 3RemeGen Co., Ltd.NCT07249632Written as Telitacicept
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentRecruitingPhase 2Nanjing University School of MedicineNCT07340463Written as Telitacicept
- A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia GravisNot yet recruitingNot applicableThe Children's Hospital of Zhejiang University School of MedicineNCT07298928Written as Telitacicept
- TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)Not yet recruitingPhase 2/3Zhongming QiuNCT07355257Written as Telitacicept 240mg
- Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis NephritisNot yet recruitingPhase 3Guixia DingNCT07052981Written as Telitacicept
- Telitacicept for the Treatment of Refractory RANot yet recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07008196Written as Telitacicept
- Telitacicept for the Treatment of Connective Tissue Disease-associated ThrombocytopeniaRecruitingPhase 2Beijing HospitalNCT05998759Written as Telitacicept
- Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia GravisNot yet recruitingNot applicableFirst Affiliated Hospital of Wenzhou Medical UniversityNCT06827587Written as Efgartigimod + Telitacicept (1-week interval) group
- Efficacy and Safety of Telitacicept in the Treatment of Systemic SclerosisRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06375005Written as Telitacicept
- Efficacy and Safety of Telitacicept in IgANRecruitingNot applicableRuijin HospitalNCT06654596Written as Telitacicept 240mg
- Telitacicept and Low-dose Steroids in Refractory Myasthenia GravisNot yet recruitingPhase 4First Affiliated Hospital of Wenzhou Medical UniversityNCT06723548Written as Telitacicept
- The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous NephropathyNot yet recruitingPhase 2Renmin Hospital of Wuhan UniversityNCT06614985Written as Telitacicept
- A Study of Telitacicept in Lupus NephritisRecruitingPhase 2RemeGen Co., Ltd.NCT05680480Written as Telitacicept 240 mg
- Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic SyndromeRecruitingPhase 3The Children's Hospital of Zhejiang University School of MedicineNCT06125405Written as Telitacicept
- The Safety and Efficacy of Telitacicept in the Treatment of Systemic SclerosisRecruitingPhase 4Peking University Third HospitalNCT06546540Written as Telitacicept
- Efficacy and Safety of Telitacicept for Prevention of Flares in SLE PatientsRecruitingNot applicableRenJi HospitalNCT06394063Written as Telitacicept
See all 53 studies that test telitacicept →
Given in every arm · 1 — telitacicept is usual care beside what is tested
Codes
What other systems call telitacicept · ClinicalTrials.gg INT001851
- MeSH (NLM) C000722462telitaciceptOne source ClinicalTrials.gov
- UNII (FDA) 1FHM3D7Z49TELITACICEPTOne source FDA
- NCI Thesaurus C166498TelitaciceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722462 | telitacicept | One source ClinicalTrials.gov |
| UNII (FDA) | 1FHM3D7Z49 | TELITACICEPT | One source FDA |
| NCI Thesaurus | C166498 | Telitacicept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.